Merck’s patent application entitled Method for Inhibiting Bone Resorption covers an increased unit dose of alendronate and other bisphosphonates for the treatment of Paget’s disease and osteoporosis.
The product covered by the patent is marketed as Fosomax® and has annual worldwide sales of over $1 billion.
The Patent Cooperation Treaty (PCT) application entered the national stage in Israel, and on allowance, the application was published for opposition purposes. Israel’s leading generic companies, Teva and Unipharm, opposed the application, alleging lack of novelty, lack of inventive step, lack of utility and non-patentable subject matter.
Following 12 days of hearings, Israel Commissioner of Patents, Dr. Noam, concluded:
The rest of this article is locked for subscribers only. Please login to continue reading.
If you don't have a login, you will need to purchase a subscription to gain access to this article, including all our online content. Please use this link and follow the steps.
For multi-user price options, or to check if your company has an existing subscription to us that we can add you to for FREE, please email Atif Choudhury at firstname.lastname@example.org